The U.S. Food and Drug Administration has approved the first oral PCSK9 inhibitor for lowering LDL cholesterol. Until now, that class of medicine was available only as an injection. This approval gives adults with high cholesterol a new daily pill to pair with diet, exercise, and existing treatment.
A New Option for High Cholesterol
Merck announced the approval of Lipfendra, known generically as enlicitide, as a once-daily 20 mg tablet. It is cleared as an addition to diet and exercise to reduce low-density lipoprotein cholesterol, often called bad cholesterol, in adults with hypercholesterolemia. The label also covers heterozygous familial hypercholesterolemia, an inherited condition that keeps cholesterol high from an early age.
The medicine is a macrocyclic peptide. It binds to a protein called PCSK9 and stops it from interacting with LDL receptors. The science sounds complicated, but the result is simple. When PCSK9 is blocked, the liver clears more cholesterol from the blood.
How PCSK9 Inhibitors Work
PCSK9 inhibitors are not new. They have been available for years, though only as injections given every few weeks. Those versions are monoclonal antibodies, and some patients found the routine hard to keep up with. Lipfendra offers the same general approach in a tablet taken once a day. For someone who dislikes needles or struggles with injection schedules, that difference is meaningful.
Statins are still the first choice for most people. The new pill is meant for those who need more cholesterol reduction even while on stable treatment.
What the Clinical Trials Showed
Merck based the approval on two Phase 3 studies from its CORALreef program. Each result was measured against a placebo at week 24.
- In the CORALreef Lipids trial, which enrolled 2,904 patients, the drug lowered LDL cholesterol by 56 percent compared with placebo.
- In the CORALreef HeFH trial, which focused on the inherited form of high cholesterol, the reduction reached 59 percent.
- Both studies also reported lower levels of other markers tied to heart disease risk, including non-HDL cholesterol and apolipoprotein B.
What the Approval Means
For people managing high cholesterol, an oral option could make long-term treatment easier to follow. Consistency is often the hardest part of any therapy, and a daily pill fits into a normal routine more naturally than a scheduled shot.
Heart health depends on steady care, regular screening, and honest conversations with a provider about personal risk. A new medicine does not replace those habits. It adds another way to reach a goal.
At Information Inside Road, we track medical and regulatory news so readers can see how it connects to wider health and business trends.
Questions Worth Raising
Not everyone with high cholesterol will switch. The right choice depends on current numbers, other conditions, and how well present treatment works. A provider can weigh cost, insurance coverage, and personal preference before suggesting a change. Anyone thinking about a new medication should discuss it first.
Staying informed helps you ask better questions and make sound decisions about your care. For more on protecting your well-being, our health news coverage follows the stories worth watching, and what you learn is worth bringing to your next appointment.